PR Newswire
BASEL, Switzerland, Aug. 7, 2017
BASEL, Switzerland, Aug. 7, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced financial results for the three months ended June 30, 2017 as well as general business updates.
Key Highlights
"This is a very exciting time for Axovant as we expect top-line results from five late-stage clinical studies over the next several months," said David Hung, M.D., chief executive officer of Axovant. "If successful, we believe that three of these studies — MINDSET, HEADWAY-DLB and the REM Behavior Disorder study — could potentially serve as pivotal studies and may, if approved, lead to new treatment options for people impacted by Alzheimer's disease and Lewy body dementia."
First Quarter Financial Summary
For the first fiscal quarter ended June 30, 2017, research and development expenses were $43.7 million, of which $6.3 million was attributable to non-cash, share-based compensation expense. General and administrative expenses for the first fiscal quarter ended June 30, 2017 were $21.5 million, of which $9.3 million was attributable to non-cash, share-based compensation expense. Net loss for the quarter ended June 30, 2017 was $69.3 million, or $0.65 per share.
Axovant held cash of $297.9 million at June 30, 2017. Net cash used in operating activities was $47.9 million for the three months ended June 30, 2017.
Development Update
Intepirdine, nelotanserin, RVT-103 and RVT-104 are being developed as potential treatments for patients with Alzheimer's disease and Lewy body dementia (LBD). The Company expects top-line results from the following late-stage clinical studies:
Additionally, events relating to the Company's investigational products were announced in June 2017 as follows:
In July, the Company presented new data relating to its intepirdine, nelotanserin and RVT-103 programs at the 2017 Alzheimer's Association International Conference (AAIC) in London, and announced new preclinical data that suggests that intepirdine may have neuroprotective properties against vascular injury and neuronal metabolic dysfunction.
In the animal model used in this study, intepirdine demonstrated neuroprotective effects under hypoxic and hypoglycemic conditions in an in vitro assay of mixed cortical neuron (MCN) cultures at clinically relevant concentrations. Specifically, when pre-treated with intepirdine for 24 hours, a decrease in lactate dehydrogenase (LDH) release, a surrogate marker of cell death, was observed in MCN cultures exposed to oxygen and glucose deprivation (p<0.05 at multiple intepirdine concentrations).
About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional and behavioral aspects of debilitating conditions such as Alzheimer's disease, Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Axovant's expectations about timing of the results for the Phase 3 MINDSET study of intepirdine in patients with Alzheimer's disease, the Phase 2b HEADWAY-DLB study of intepirdine in patients with DLB, the Phase 2 gait and balance study in patients with Alzheimer's disease, DLB and PDD, the Phase 2 study of nelotanserin in patients with LBD suffering from visual hallucinations, the Phase 2 study of nelotanserin in patients with LBD suffering from RBD, the proof of concept and related studies of RVT-103 and RVT-104 in patients with Alzheimer's disease and DLB, and other elements of its clinical development and regulatory strategy. Forward-looking statements can be identified by the words "believe," "anticipate," "continue," "estimate," "project," "expect," "plan," "potential," "intends," "will," "would," "could," "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates intepirdine, nelotanserin, RVT-103 and RVT-104; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. There can be no assurance that the clinical programs for intepirdine, nelotanserin, RVT-103 or RVT-104 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q to be filed with the Securities and Exchange Commission on or about August 7, 2017, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this press release and speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law.
AXOVANT SCIENCES LTD. | |||||||
| |||||||
| |||||||
| |||||||
| | | | ||||
| Three Months Ended June 30, 2017 | | Three Months Ended June 30, 2016 | ||||
Operating expenses: | | | | ||||
Research and development expenses | | | | ||||
(includes share-based compensation expense of $6,256 and $4,964 for the three months ended June 30, 2017 and 2016, respectively) | $ | 43,712 | | | $ | 25,276 | |
General and administrative expenses | | | | ||||
(includes share-based compensation expense of $9,344 and $6,597 for the three months ended June 30, 2017 and 2016, respectively) | 21,518 | | | 12,631 | | ||
Total operating expenses | 65,230 | | | 37,907 | | ||
| | | | ||||
Interest expense | 1,874 | | | — | | ||
Other income | (357) | | | — | | ||
| | | | ||||
Loss before provision for income taxes | (66,747) | | | (37,907) | | ||
| | | | ||||
Income tax expense | 2,519 | | | 148 | | ||
| | | | ||||
Net loss | $ | (69,266) | | | $ | (38,055) | |
| | | | ||||
Net loss per common share — basic and diluted | $ | (0.65) | | | $ | (0.38) | |
Weighted average common shares outstanding — basic and diluted | 106,400,912 | | | 99,150,000 | |
AXOVANT SCIENCES LTD. | |||||||
| |||||||
| |||||||
| |||||||
| |||||||
| June 30, 2017 | | March 31, 2017 | ||||
Assets | | | | ||||
Current assets: | | | | ||||
Cash | $ | 297,858 | | | $ | 212,573 | |
Prepaid expenses and other current assets | 7,627 | | | 6,457 | | ||
Income tax receivable | 1,224 | | | 658 | | ||
Total current assets | 306,709 | | | 219,688 | | ||
Property and equipment, net | 2,294 | | | 142 | | ||
Deferred tax assets | — | | | 2,709 | | ||
Total assets | $ | 309,003 | | | $ | 222,539 | |
| | | | ||||
Liabilities and Shareholders' Equity | | | | ||||
Current liabilities: | | | | ||||
Accounts payable | $ | 8,547 | | | $ | 8,551 | |
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. Werbung Mehr Nachrichten zur Sio Gene Therapies Inc. Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |